中华眼视光学与视觉科学杂志
中華眼視光學與視覺科學雜誌
중화안시광학여시각과학잡지
CHINESE JOURNAL OF OPTOMETRY OPHTHALMOLOGY AND VISUAL SCIENCE
2014年
10期
615-621
,共7页
眼睑疾病%睑板腺%睑板腺功能障碍%显微镜检查,共焦%手术
眼瞼疾病%瞼闆腺%瞼闆腺功能障礙%顯微鏡檢查,共焦%手術
안검질병%검판선%검판선공능장애%현미경검사,공초%수술
Eyelid diseases%Meibomian glands%Meibomian gland dysfunction%Microscopy,confocal%Surgery
目的 探讨睑板腺腺管探通术治疗睑板腺功能障碍(MGD)的临床疗效及安全性.方法 前瞻性配伍组设计.111例睑板腺功能障碍患者,按性别年龄相匹配分为3组,每组37人(37眼),选择症状体征较重的眼作为观察眼.常规治疗组采用抗生素激素滴眼液+人工泪液+局部物理治疗;腺管探通术组在常规治疗组的治疗基础上用直径仅76 μm的不锈钢探针(美国Rhein Medical公司),每只眼探通6~9个睑板腺腺管;腺管探通联合管内注药组在腺管探通组治疗基础上,探通术中管内注入适量妥布霉素地塞米松滴眼液.分别于治疗前和治疗后1个月观察MGD患者主观症状指标眼表疾病指数(OSDI)量表、泪膜破裂时间(BUT)、基础泪液分泌试验(SIT)检查、角膜荧光素染色(CFS)、裂隙灯显微镜下睑缘评分共5项指标的变化并做对比分析.对实施探通术2组的MGD患者分别于探通前及探通后1个月进行共聚焦显微镜检查,观察睑板腺腺泡单位有无损伤改变,以评价探通术的安全性.组内定量指标比较采用配对t检验,多组之间比较采用配伍组设计的两因素方差分析,差异有显著性后采用q检验进行两两比较.结果 ①3组MGD患者治疗前OSDI、BUT、CFS、SIT、裂隙灯下睑缘评分共5项观测指标基线值对比差异无统计学意义.②治疗后1个月3组之间5项检测指标差异有统计学意义(F=4.68、4.17、3.98、3.67、4.12,P<0.05);腺管探通术组与腺管探通联合管内注药组各项观测指标改善程度均优于常规治疗组,差异有统计学意义(P<0.05).腺管探通联合注药组经治疗后改善程度虽优于单纯探通术组,但差异无统计学意义.③实施探通术的2组MGD患者治疗后5项观测指标较治疗前均有显著改善,差异有统计学意义(腺管探通术组:t=2.543、2.343、2.456、2.132、2.237;腺管探通联合管内注药组:t=2.713、2.443、2.496、2.143、2.249,P均<0.05).常规治疗组MGD患者经治疗后与术前相比虽有改善,但差异无统计学意义.④共聚焦显微镜下睑板腺腺泡单位因光学切面不同,呈现不同形态,有圆形、卵圆形、长条形、不规则形等,腺泡外圈为轮胎样上皮细胞,伴有高亮反光颗粒,胞腔内呈灰色伴点状高反光分泌物,团块状聚集分布,排列不规整.探通后未见萎缩腺泡增加或疤痕形成.结论 睑板腺腺管探通术能直接缓解睑板腺管阻塞,从而快速地缓解阻塞性MGD患者的症状和体征,是一种新的安全有效的治疗方法.
目的 探討瞼闆腺腺管探通術治療瞼闆腺功能障礙(MGD)的臨床療效及安全性.方法 前瞻性配伍組設計.111例瞼闆腺功能障礙患者,按性彆年齡相匹配分為3組,每組37人(37眼),選擇癥狀體徵較重的眼作為觀察眼.常規治療組採用抗生素激素滴眼液+人工淚液+跼部物理治療;腺管探通術組在常規治療組的治療基礎上用直徑僅76 μm的不鏽鋼探針(美國Rhein Medical公司),每隻眼探通6~9箇瞼闆腺腺管;腺管探通聯閤管內註藥組在腺管探通組治療基礎上,探通術中管內註入適量妥佈黴素地塞米鬆滴眼液.分彆于治療前和治療後1箇月觀察MGD患者主觀癥狀指標眼錶疾病指數(OSDI)量錶、淚膜破裂時間(BUT)、基礎淚液分泌試驗(SIT)檢查、角膜熒光素染色(CFS)、裂隙燈顯微鏡下瞼緣評分共5項指標的變化併做對比分析.對實施探通術2組的MGD患者分彆于探通前及探通後1箇月進行共聚焦顯微鏡檢查,觀察瞼闆腺腺泡單位有無損傷改變,以評價探通術的安全性.組內定量指標比較採用配對t檢驗,多組之間比較採用配伍組設計的兩因素方差分析,差異有顯著性後採用q檢驗進行兩兩比較.結果 ①3組MGD患者治療前OSDI、BUT、CFS、SIT、裂隙燈下瞼緣評分共5項觀測指標基線值對比差異無統計學意義.②治療後1箇月3組之間5項檢測指標差異有統計學意義(F=4.68、4.17、3.98、3.67、4.12,P<0.05);腺管探通術組與腺管探通聯閤管內註藥組各項觀測指標改善程度均優于常規治療組,差異有統計學意義(P<0.05).腺管探通聯閤註藥組經治療後改善程度雖優于單純探通術組,但差異無統計學意義.③實施探通術的2組MGD患者治療後5項觀測指標較治療前均有顯著改善,差異有統計學意義(腺管探通術組:t=2.543、2.343、2.456、2.132、2.237;腺管探通聯閤管內註藥組:t=2.713、2.443、2.496、2.143、2.249,P均<0.05).常規治療組MGD患者經治療後與術前相比雖有改善,但差異無統計學意義.④共聚焦顯微鏡下瞼闆腺腺泡單位因光學切麵不同,呈現不同形態,有圓形、卵圓形、長條形、不規則形等,腺泡外圈為輪胎樣上皮細胞,伴有高亮反光顆粒,胞腔內呈灰色伴點狀高反光分泌物,糰塊狀聚集分佈,排列不規整.探通後未見萎縮腺泡增加或疤痕形成.結論 瞼闆腺腺管探通術能直接緩解瞼闆腺管阻塞,從而快速地緩解阻塞性MGD患者的癥狀和體徵,是一種新的安全有效的治療方法.
목적 탐토검판선선관탐통술치료검판선공능장애(MGD)적림상료효급안전성.방법 전첨성배오조설계.111례검판선공능장애환자,안성별년령상필배분위3조,매조37인(37안),선택증상체정교중적안작위관찰안.상규치료조채용항생소격소적안액+인공루액+국부물리치료;선관탐통술조재상규치료조적치료기출상용직경부76 μm적불수강탐침(미국Rhein Medical공사),매지안탐통6~9개검판선선관;선관탐통연합관내주약조재선관탐통조치료기출상,탐통술중관내주입괄량타포매소지새미송적안액.분별우치료전화치료후1개월관찰MGD환자주관증상지표안표질병지수(OSDI)량표、루막파렬시간(BUT)、기출루액분비시험(SIT)검사、각막형광소염색(CFS)、렬극등현미경하검연평분공5항지표적변화병주대비분석.대실시탐통술2조적MGD환자분별우탐통전급탐통후1개월진행공취초현미경검사,관찰검판선선포단위유무손상개변,이평개탐통술적안전성.조내정량지표비교채용배대t검험,다조지간비교채용배오조설계적량인소방차분석,차이유현저성후채용q검험진행량량비교.결과 ①3조MGD환자치료전OSDI、BUT、CFS、SIT、렬극등하검연평분공5항관측지표기선치대비차이무통계학의의.②치료후1개월3조지간5항검측지표차이유통계학의의(F=4.68、4.17、3.98、3.67、4.12,P<0.05);선관탐통술조여선관탐통연합관내주약조각항관측지표개선정도균우우상규치료조,차이유통계학의의(P<0.05).선관탐통연합주약조경치료후개선정도수우우단순탐통술조,단차이무통계학의의.③실시탐통술적2조MGD환자치료후5항관측지표교치료전균유현저개선,차이유통계학의의(선관탐통술조:t=2.543、2.343、2.456、2.132、2.237;선관탐통연합관내주약조:t=2.713、2.443、2.496、2.143、2.249,P균<0.05).상규치료조MGD환자경치료후여술전상비수유개선,단차이무통계학의의.④공취초현미경하검판선선포단위인광학절면불동,정현불동형태,유원형、란원형、장조형、불규칙형등,선포외권위륜태양상피세포,반유고량반광과립,포강내정회색반점상고반광분비물,단괴상취집분포,배렬불규정.탐통후미견위축선포증가혹파흔형성.결론 검판선선관탐통술능직접완해검판선관조새,종이쾌속지완해조새성MGD환자적증상화체정,시일충신적안전유효적치료방법.
Objective To investigate the clinical efficacy and safety of intraductal meibomian gland probing in the treatment of patients with meibomian gland dysfunction (MGD).Methods In a prospective randomized block design,111 consecutive patients (111 eyes) with MGD were divided into 3 groups.All subjects were age-and sex-matched among the 3 groups.The eye selected for the study in each subject was chosen on the basis of the most obvious symptoms.There were 37 eyes in each group.The conventional treatment group was treated only with antibiotic eye drops combined with topical steroids+artificial tears+local physical therapy; MGD patients in the intraductal probing group underwent intraductal probing with steel probes (Rhein Medical,Inc.USA) and 6~9 meibomian glands were probed in each eye; and the third group underwent intraductal probing combined with a drug (0.5% tobramycin dexamethasone eye drops) injected into the intraductal meibomian gland during the probing procedure.All subjects underwent sequential examinations before and after treatment as follows:evaluation of ocular surface disease symptoms using the ocular surface disease index (OSDI); tear film break-up time (BUT); corneal fluorescein staining (CFS); Schirmer I test (SIT),and lid margin and ocular surface examination by slit lamp.The parameters among the 3 groups were investigated and compared before treatment and 1 month after treatment.Confocal microscope was performed to detect the safety of the intraductal meibomian gland probing by observing both the morphology and density of meibomian gland (MG) acinar units.The data among the three groups were randomly compared by a two-way ANOVA and q test (Newman-Keuls); a paired t test was used to analyze the parameters in each group before treatment and 1 month after treatment.Results ①Before treatment,there were no statistical differences among the three groups in OSDI,BUT,CFS,SIT,or lid margin scores (P>0.05).②There were statistical differences among the three groups 1 month after treatment (F=4.68,4.17,3.98,3.67,4.12,P<0.05).The changes in every parameter in the conventional treatment group were significantly lower than for those in the intraductal probing group (P<0.05) and in the intraductal probing group that received drug injections (P<0.05).Improvement was better in the intraductal probing group that received injections compared to the intraductal probing group but no statistically significant differences were seen in the parameters.③ 1 month after treatment:except for the conventional treatment group,significant differences were noted in the data of OSDI,BUT,CFS,Schirmer I test,and lid margin scores in the intraductal probing group (t=2.543,2.343,2.456,2.132,2.237,respectively,P<0.05) and in the intraductal probing with drug injection group (t=2.713,2.443,2.496,2.143,2.249,respectively,P<0.05).④The MG acinar cells can be clearly observed with confocal microscope.MG acinar cells showed that different forms were due to the location in different optical sections.The outer sections of MG acinar cells were tire-like,accompanied by bright reflective and gray cell cavities with highly reflective dot secretion.MGs were distributed in group-like aggregations and arranged irregularly.There were no degenerative changes in the morphology of MG acinar units as well as MG scars 1 month after probing.Conclusion Intraductal meibomian gland probing seems to provide rapid and lasting symptom relief and significant improvement in symptoms and signs of MGD in patients.Intraductal meibomian gland probing is a safe,effective technique for MGD.